Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 103 entries
Sorted by: Best Match Show Resources per page
Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.

Journal of medicinal chemistry

Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N.
PMID: 34982568
J Med Chem. 2022 Jan 13;65(1):343-368. doi: 10.1021/acs.jmedchem.1c01509. Epub 2022 Jan 04.

Inhibition of oxidative phosphorylation (OXPHOS) is a promising therapeutic strategy for select cancers that are dependent on aerobic metabolism. Here, we report the discovery, optimization, and structure-activity relationship (SAR) study of a series of novel OXPHOS inhibitors. The hit...

Cite
Xue D, Xu Y, Kyani A, et al. Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors. J Med Chem. 2022;65(1):343-368doi: 10.1021/acs.jmedchem.1c01509.
Xue, D., Xu, Y., Kyani, A., Roy, J., Dai, L., Sun, D., & Neamati, N. (2022). Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors. Journal of medicinal chemistry, 65(1), 343-368. https://doi.org/10.1021/acs.jmedchem.1c01509
Xue, Ding, et al. "Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors." Journal of medicinal chemistry vol. 65,1 (2022): 343-368. doi: https://doi.org/10.1021/acs.jmedchem.1c01509
Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N. Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors. J Med Chem. 2022 Jan 13;65(1):343-368. doi: 10.1021/acs.jmedchem.1c01509. Epub 2022 Jan 04. PMID: 34982568.
Copy Download .nbib Format: NLM
The Impact of Inflation and Its Uncertainty on Pharmaceutical Prices: Evidence from Iran.

Iranian journal of pharmaceutical research : IJPR

Soleimani Movahed M, Rezapour A, Vahedi S, Abolghasem Gorji H, Bagherzadeh R, Nemati A, Nemati G, Mohammad-Pour S.
PMID: 34903972
Iran J Pharm Res. 2021;20(3):94-101. doi: 10.22037/ijpr.2020.114071.14646.

Pharmaceutical productions are recognized as an essential commodity in the economical literature; therefore, an increase in their prices leads to an increase in the household budget. Currently, about 15-20% of the entire health expenditure in Iran is allocated to...

Cite
Soleimani Movahed M, Rezapour A, Vahedi S, et al. The Impact of Inflation and Its Uncertainty on Pharmaceutical Prices: Evidence from Iran. Iran J Pharm Res. 2021;20(3):94-101doi: 10.22037/ijpr.2020.114071.14646.
Soleimani Movahed, M., Rezapour, A., Vahedi, S., Abolghasem Gorji, H., Bagherzadeh, R., Nemati, A., Nemati, G., & Mohammad-Pour, S. (2021). The Impact of Inflation and Its Uncertainty on Pharmaceutical Prices: Evidence from Iran. Iranian journal of pharmaceutical research : IJPR, 20(3), 94-101. https://doi.org/10.22037/ijpr.2020.114071.14646
Soleimani Movahed, Maryam, et al. "The Impact of Inflation and Its Uncertainty on Pharmaceutical Prices: Evidence from Iran." Iranian journal of pharmaceutical research : IJPR vol. 20,3 (2021): 94-101. doi: https://doi.org/10.22037/ijpr.2020.114071.14646
Soleimani Movahed M, Rezapour A, Vahedi S, Abolghasem Gorji H, Bagherzadeh R, Nemati A, Nemati G, Mohammad-Pour S. The Impact of Inflation and Its Uncertainty on Pharmaceutical Prices: Evidence from Iran. Iran J Pharm Res. 2021;20(3):94-101. doi: 10.22037/ijpr.2020.114071.14646. PMID: 34903972; PMCID: PMC8653671.
Copy Download .nbib Format: NLM
Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension.

Hepatic medicine : evidence and research

Gioia S, Riggio O, Nardelli S, d'Amati G, Ridola L.
PMID: 34764704
Hepat Med. 2021 Nov 03;13:105-111. doi: 10.2147/HMER.S282674. eCollection 2021.

The term porto-sinusoidal vascular disease (PSVD) has been recently proposed to replace the term idiopathic non-cirrhotic portal hypertension (INCPH) to describe patients with or without signs of portal hypertension and typical histological lesions involving the portal venules or sinusoids...

Cite
Gioia S, Riggio O, Nardelli S, et al. Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension. Hepat Med. 2021;13:105-111doi: 10.2147/HMER.S282674.
Gioia, S., Riggio, O., Nardelli, S., d'Amati, G., & Ridola, L. (2021). Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension. Hepatic medicine : evidence and research, 13105-111. https://doi.org/10.2147/HMER.S282674
Gioia, Stefania, et al. "Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension." Hepatic medicine : evidence and research vol. 13 (2021): 105-111. doi: https://doi.org/10.2147/HMER.S282674
Gioia S, Riggio O, Nardelli S, d'Amati G, Ridola L. Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension. Hepat Med. 2021 Nov 03;13:105-111. doi: 10.2147/HMER.S282674. eCollection 2021. PMID: 34764704; PMCID: PMC8572743.
Copy Download .nbib Format: NLM
Results of Adrenalectomy for Isolated, Metachronous Metastasis of Breast Cancer: A Retrospective Cohort Study.

Frontiers in surgery

Illuminati G, Pasqua R, D'Ermo G, Girolami M, Cerbelli B, D'Amati G, Carboni F, Fiori E.
PMID: 34179068
Front Surg. 2021 Jun 09;8:671424. doi: 10.3389/fsurg.2021.671424. eCollection 2021.

No abstract available.

Cite
Illuminati G, Pasqua R, D'Ermo G, et al. Results of Adrenalectomy for Isolated, Metachronous Metastasis of Breast Cancer: A Retrospective Cohort Study. Front Surg. 2021;8:671424doi: 10.3389/fsurg.2021.671424.
Illuminati, G., Pasqua, R., D'Ermo, G., Girolami, M., Cerbelli, B., D'Amati, G., Carboni, F., & Fiori, E. (2021). Results of Adrenalectomy for Isolated, Metachronous Metastasis of Breast Cancer: A Retrospective Cohort Study. Frontiers in surgery, 8671424. https://doi.org/10.3389/fsurg.2021.671424
Illuminati, Giulio, et al. "Results of Adrenalectomy for Isolated, Metachronous Metastasis of Breast Cancer: A Retrospective Cohort Study." Frontiers in surgery vol. 8 (2021): 671424. doi: https://doi.org/10.3389/fsurg.2021.671424
Illuminati G, Pasqua R, D'Ermo G, Girolami M, Cerbelli B, D'Amati G, Carboni F, Fiori E. Results of Adrenalectomy for Isolated, Metachronous Metastasis of Breast Cancer: A Retrospective Cohort Study. Front Surg. 2021 Jun 09;8:671424. doi: 10.3389/fsurg.2021.671424. eCollection 2021. PMID: 34179068; PMCID: PMC8219849.
Copy Download .nbib Format: NLM
A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight.

ACS pharmacology & translational science

Cuthbertson CR, Arabzada Z, Bankhead A, Kyani A, Neamati N.
PMID: 33860190
ACS Pharmacol Transl Sci. 2021 Mar 01;4(2):624-646. doi: 10.1021/acsptsci.0c00223. eCollection 2021 Apr 09.

Metabolic reprogramming is a key hallmark of cancer and shifts cellular metabolism to meet the demands of biomass production necessary for abnormal cell reproduction. One-carbon metabolism (1CM) contributes to many biosynthetic pathways that fuel growth and is comprised of...

Cite
Cuthbertson CR, Arabzada Z, Bankhead A, et al. A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight. ACS Pharmacol Transl Sci. 2021;4(2):624-646doi: 10.1021/acsptsci.0c00223.
Cuthbertson, C. R., Arabzada, Z., Bankhead, A., Kyani, A., & Neamati, N. (2021). A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight. ACS pharmacology & translational science, 4(2), 624-646. https://doi.org/10.1021/acsptsci.0c00223
Cuthbertson, Christine R, et al. "A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight." ACS pharmacology & translational science vol. 4,2 (2021): 624-646. doi: https://doi.org/10.1021/acsptsci.0c00223
Cuthbertson CR, Arabzada Z, Bankhead A, Kyani A, Neamati N. A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight. ACS Pharmacol Transl Sci. 2021 Mar 01;4(2):624-646. doi: 10.1021/acsptsci.0c00223. eCollection 2021 Apr 09. PMID: 33860190; PMCID: PMC8033767.
Copy Download .nbib Format: NLM
Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles.

ACS medicinal chemistry letters

Sanna V, Youssef MF, Pala N, Rogolino D, Carcelli M, Singh PK, Sanchez T, Neamati N, Sechi M.
PMID: 32435396
ACS Med Chem Lett. 2020 Mar 20;11(5):857-861. doi: 10.1021/acsmedchemlett.9b00648. eCollection 2020 May 14.

Gold nanoparticles (GNPs) have been proposed as carriers for drugs to improve their intrinsic therapeutic activities and to overcome pharmacokinetic problems. In this study, novel nanosystems constituted by a model β-diketo acid (DKA) grafted to the surface of GNPs...

Cite
Sanna V, Youssef MF, Pala N, et al. Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles. ACS Med Chem Lett. 2020;11(5):857-861doi: 10.1021/acsmedchemlett.9b00648.
Sanna, V., Youssef, M. F., Pala, N., Rogolino, D., Carcelli, M., Singh, P. K., Sanchez, T., Neamati, N., & Sechi, M. (2020). Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles. ACS medicinal chemistry letters, 11(5), 857-861. https://doi.org/10.1021/acsmedchemlett.9b00648
Sanna, Vanna, et al. "Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles." ACS medicinal chemistry letters vol. 11,5 (2020): 857-861. doi: https://doi.org/10.1021/acsmedchemlett.9b00648
Sanna V, Youssef MF, Pala N, Rogolino D, Carcelli M, Singh PK, Sanchez T, Neamati N, Sechi M. Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles. ACS Med Chem Lett. 2020 Mar 20;11(5):857-861. doi: 10.1021/acsmedchemlett.9b00648. eCollection 2020 May 14. PMID: 32435396; PMCID: PMC7236234.
Copy Download .nbib Format: NLM
Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer.

Cancers

Cerbelli B, Scagnoli S, Mezi S, De Luca A, Pisegna S, Amabile MI, Roberto M, Fortunato L, Costarelli L, Pernazza A, Strigari L, Della Rocca C, Marchetti P, d'Amati G, Botticelli A.
PMID: 32947953
Cancers (Basel). 2020 Sep 16;12(9). doi: 10.3390/cancers12092648.

Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) can predict better survival outcomes in patients with early triple negative breast cancer (TNBC). Tumor infiltrating lymphocytes (TILs), Programmed Death-Ligand 1 (PD-L1), and Cluster of Differentiation 73 (CD73) are immune-related biomarkers...

Cite
Cerbelli B, Scagnoli S, Mezi S, et al. Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. Cancers (Basel). 2020;12(9)doi: 10.3390/cancers12092648.
Cerbelli, B., Scagnoli, S., Mezi, S., De Luca, A., Pisegna, S., Amabile, M. I., Roberto, M., Fortunato, L., Costarelli, L., Pernazza, A., Strigari, L., Della Rocca, C., Marchetti, P., d'Amati, G., & Botticelli, A. (2020). Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. Cancers, 12(9), . https://doi.org/10.3390/cancers12092648
Cerbelli, Bruna, et al. "Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer." Cancers vol. 12,9 (2020). doi: https://doi.org/10.3390/cancers12092648
Cerbelli B, Scagnoli S, Mezi S, De Luca A, Pisegna S, Amabile MI, Roberto M, Fortunato L, Costarelli L, Pernazza A, Strigari L, Della Rocca C, Marchetti P, d'Amati G, Botticelli A. Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. Cancers (Basel). 2020 Sep 16;12(9). doi: 10.3390/cancers12092648. PMID: 32947953; PMCID: PMC7565153.
Copy Download .nbib Format: NLM
Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL).

Cancers

Napoletano C, Steentoff C, Battisti F, Ye Z, Rahimi H, Zizzari IG, Dionisi M, Cerbelli B, Tomao F, French D, d'Amati G, Panici PB, Vakhrushev S, Clausen H, Nuti M, Rughetti A.
PMID: 33019700
Cancers (Basel). 2020 Oct 01;12(10). doi: 10.3390/cancers12102841.

Glycosylation, the posttranslational linking of sugar molecules to proteins, is notoriously altered during tumor transformation. More specifically in carcinomas, GalNAc-type

Cite
Napoletano C, Steentoff C, Battisti F, et al. Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL). Cancers (Basel). 2020;12(10)doi: 10.3390/cancers12102841.
Napoletano, C., Steentoff, C., Battisti, F., Ye, Z., Rahimi, H., Zizzari, I. G., Dionisi, M., Cerbelli, B., Tomao, F., French, D., d'Amati, G., Panici, P. B., Vakhrushev, S., Clausen, H., Nuti, M., & Rughetti, A. (2020). Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL). Cancers, 12(10), . https://doi.org/10.3390/cancers12102841
Napoletano, Chiara, et al. "Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL)." Cancers vol. 12,10 (2020). doi: https://doi.org/10.3390/cancers12102841
Napoletano C, Steentoff C, Battisti F, Ye Z, Rahimi H, Zizzari IG, Dionisi M, Cerbelli B, Tomao F, French D, d'Amati G, Panici PB, Vakhrushev S, Clausen H, Nuti M, Rughetti A. Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL). Cancers (Basel). 2020 Oct 01;12(10). doi: 10.3390/cancers12102841. PMID: 33019700; PMCID: PMC7600217.
Copy Download .nbib Format: NLM
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.

Vaccines

Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D'Amati G, Della Rocca C, Mezi S, Gelibter A, Giusti R, Cortesi E, Ascierto PA, Nuti M, Marchetti P.
PMID: 32353934
Vaccines (Basel). 2020 Apr 28;8(2). doi: 10.3390/vaccines8020203.

Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma and many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Unfortunately, only a minority of patients have a long-term benefit, while the remaining...

Cite
Botticelli A, Cirillo A, Scagnoli S, et al. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines (Basel). 2020;8(2)doi: 10.3390/vaccines8020203.
Botticelli, A., Cirillo, A., Scagnoli, S., Cerbelli, B., Strigari, L., Cortellini, A., Pizzuti, L., Vici, P., De Galitiis, F., Di Pietro, F. R., Cerbelli, E., Ghidini, M., D'Amati, G., Della Rocca, C., Mezi, S., Gelibter, A., Giusti, R., Cortesi, E., Ascierto, P. A., Nuti, M., & Marchetti, P. (2020). The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines, 8(2), . https://doi.org/10.3390/vaccines8020203
Botticelli, Andrea, et al. "The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy." Vaccines vol. 8,2 (2020). doi: https://doi.org/10.3390/vaccines8020203
Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D'Amati G, Della Rocca C, Mezi S, Gelibter A, Giusti R, Cortesi E, Ascierto PA, Nuti M, Marchetti P. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines (Basel). 2020 Apr 28;8(2). doi: 10.3390/vaccines8020203. PMID: 32353934; PMCID: PMC7349154.
Copy Download .nbib Format: NLM
The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

ACS pharmacology & translational science

Cuthbertson CR, Guo H, Kyani A, Madak JT, Arabzada Z, Neamati N.
PMID: 33344900
ACS Pharmacol Transl Sci. 2020 Nov 23;3(6):1242-1252. doi: 10.1021/acsptsci.0c00124. eCollection 2020 Dec 11.

The dihydroorotate dehydrogenase (DHODH) inhibitor brequinar failed all clinical trials for solid tumors. To investigate mechanisms to increase brequinar's efficacy, we employed a combination strategy to simultaneously inhibit the nucleotide salvage pathways. Brequinar is synergistic with the equilibrative nucleoside...

Cite
Cuthbertson CR, Guo H, Kyani A, et al. The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. ACS Pharmacol Transl Sci. 2020;3(6):1242-1252doi: 10.1021/acsptsci.0c00124.
Cuthbertson, C. R., Guo, H., Kyani, A., Madak, J. T., Arabzada, Z., & Neamati, N. (2020). The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. ACS pharmacology & translational science, 3(6), 1242-1252. https://doi.org/10.1021/acsptsci.0c00124
Cuthbertson, Christine R, et al. "The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors." ACS pharmacology & translational science vol. 3,6 (2020): 1242-1252. doi: https://doi.org/10.1021/acsptsci.0c00124
Cuthbertson CR, Guo H, Kyani A, Madak JT, Arabzada Z, Neamati N. The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. ACS Pharmacol Transl Sci. 2020 Nov 23;3(6):1242-1252. doi: 10.1021/acsptsci.0c00124. eCollection 2020 Dec 11. PMID: 33344900; PMCID: PMC7737209.
Copy Download .nbib Format: NLM
Correction to: Cardiac hypertrophy at autopsy.

Virchows Archiv : an international journal of pathology

Basso C, Michaud K, d'Amati G, Banner J, Lucena J, Cunningham K, Leone O, Vink A, van der Wal AC, Sheppard MN.
PMID: 33987695
Virchows Arch. 2021 Jul;479(1):95. doi: 10.1007/s00428-021-03118-1.

No abstract available.

Cite
Basso C, Michaud K, d'Amati G, et al. Correction to: Cardiac hypertrophy at autopsy. Virchows Arch. 2021;479(1):95doi: 10.1007/s00428-021-03118-1.
Basso, C., Michaud, K., d'Amati, G., Banner, J., Lucena, J., Cunningham, K., Leone, O., Vink, A., van der Wal, A. C., Sheppard, M. N. (2021). Correction to: Cardiac hypertrophy at autopsy. Virchows Archiv : an international journal of pathology, 479(1), 95. https://doi.org/10.1007/s00428-021-03118-1
Basso, Cristina, et al. "Correction to: Cardiac hypertrophy at autopsy." Virchows Archiv : an international journal of pathology vol. 479,1 (2021): 95. doi: https://doi.org/10.1007/s00428-021-03118-1
Basso C, Michaud K, d'Amati G, Banner J, Lucena J, Cunningham K, Leone O, Vink A, van der Wal AC, Sheppard MN. Correction to: Cardiac hypertrophy at autopsy. Virchows Arch. 2021 Jul;479(1):95. doi: 10.1007/s00428-021-03118-1. PMID: 33987695; PMCID: PMC8329813.
Copy Download .nbib Format: NLM
Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response.

Oncogenesis

Giuli MV, Diluvio G, Giuliani E, Franciosa G, Di Magno L, Pignataro MG, Tottone L, Nicoletti C, Besharat ZM, Peruzzi G, Pelullo M, Palermo R, Canettieri G, Talora C, d'Amati G, Bellavia D, Screpanti I, Checquolo S.
PMID: 33071287
Oncogenesis. 2020 Oct 18;9(10):93. doi: 10.1038/s41389-020-00279-7.

Unfolded protein response (UPR) is a conserved adaptive response that tries to restore protein homeostasis after endoplasmic reticulum (ER) stress. Recent studies highlighted the role of UPR in acute leukemias and UPR targeting has been suggested as a therapeutic...

Cite
Giuli MV, Diluvio G, Giuliani E, et al. Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response. Oncogenesis. 2020;9(10):93doi: 10.1038/s41389-020-00279-7.
Giuli, M. V., Diluvio, G., Giuliani, E., Franciosa, G., Di Magno, L., Pignataro, M. G., Tottone, L., Nicoletti, C., Besharat, Z. M., Peruzzi, G., Pelullo, M., Palermo, R., Canettieri, G., Talora, C., d'Amati, G., Bellavia, D., Screpanti, I., & Checquolo, S. (2020). Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response. Oncogenesis, 9(10), 93. https://doi.org/10.1038/s41389-020-00279-7
Giuli, Maria Valeria, et al. "Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response." Oncogenesis vol. 9,10 (2020): 93. doi: https://doi.org/10.1038/s41389-020-00279-7
Giuli MV, Diluvio G, Giuliani E, Franciosa G, Di Magno L, Pignataro MG, Tottone L, Nicoletti C, Besharat ZM, Peruzzi G, Pelullo M, Palermo R, Canettieri G, Talora C, d'Amati G, Bellavia D, Screpanti I, Checquolo S. Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response. Oncogenesis. 2020 Oct 18;9(10):93. doi: 10.1038/s41389-020-00279-7. PMID: 33071287; PMCID: PMC7569087.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 103 entries